Plunkett Research Online: Liminal BioSciences Inc

LIMINAL BIOSCIENCES INC (LMNL:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Liminal BioSciences, Inc. is a global clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases with high unmet medical need. Liminal’s deep understanding of certain biological targets and pathways include f.....



Liminal BioSciences Inc
Ticker: LMNL
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 450 781-0115
Fax: 450 781-4477
Address: 440, Boulevard Armand-Frappier
Suite 300
Laval, QC H7V 4B4 Canada

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Plasma Technologies
Clinical-Stage Biopharmaceuticals
Drug Discovery
Drug Development
Contacts Description

Kenneth Galbraith CEO/Director
John Moran Chief Medical Officer
See More
Liminal BioSciences, Inc. is a global clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases with high unmet medical need. Liminal’s deep understanding of certain biological targets and pathways include f.....See More See More

Auditor: PricewaterhouseCoopers LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2020 2019 2018 2017 2016 2015
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Fezagepras
Ryplazim
Name Title Salary (US$) Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: